Cynata Therapeutics Limited
CYYNF
Other OTC0.22
USD
- -
- -
ISIN
AU000000CYP7
Return %
Stock
S&P500
1Y
48.33
26.84
3Y
-7.29
77.03
5Y
-55.50
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Kilian Kelly
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Cubitt Street Cremorne VIC Australia 3121
- IPO Date
- May 26, 2015
- Website
- cynata.com
- Similar Companies
- Business
- Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in the development and commercialization of proprietary therapeutic stem cell platform technology under the Cymerus brand. Its core products include induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC) therapies, with key candidates such as CYP-001, which has completed Phase 2 clinical trials for treating graft-versus-host disease (GvHD); CYP-004, in Phase 3 trials for osteoarthritis treatment; and CYP-006TK, a novel polymer-coated silicon wound dressing for diabetic wounds. The company also develops therapies targeting asthma, heart attack, coronary artery disease, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Founded in 2012 and headquartered in Melbourne, Australia, Cynata leverages its Cymerus platform for scalable and consistent manufacture of stem cell therapies without donor variability issues. It operates primarily in the Australian market but is engaged in clinical trials and intellectual property development internationally. Recent major changes include progressing the Phase 2 graft-versus-host disease trial with completion expected in late 2025 and the Phase 3 osteoarthritis trial with patient recruitment completed and results anticipated in 2026. The company strengthened its intellectual property portfolio with new patent grants and applications in Singapore and Hong Kong and launched research collaborations such as the SMART CRC initiative. Cynata also reported a net loss of $9.39 million for the fiscal year ending June 2025 but maintains a strong cash balance expected to fund operations into mid-2026. Cynata Therapeutics is advancing innovative regenerative medicine therapies designed to address critical unmet medical needs, with a clear focus on clinical trial progression, intellectual property expansion, and strategic partnerships to support its commercialization pathway and global market reach.
Cynata Therapeutics Limited (CYYNF) Discusses Imminent Clinical Trial Readouts and Key Milestones in Osteoarthritis and Graft-versus-Host Disease Transcript
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Cynata Therapeutics (OTCMKTS:CYYNF) vs. Exelixis (NASDAQ:EXEL) Financial Survey
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts